Sarah Blankstein

FDA Finalizes Guidance On Communication Of Scientific Information On Unapproved Uses And Releases Updated First Amendment Analysis

Non-binding Guidance: Clinical Trial Diversity In Focus (Podcast)

Non-Binding Guidance: Preview Of The Second Annual Ropes & Gray Rare Disease Forum (Podcast)

Inching Toward Harmonization: FDA Finalizes Rule On IRB Waiver Of Informed Consent For Minimal Risk Studies

U.S. Life Sciences Regulatory And Compliance Outlook 2024 (Part II): Product Development And Pricing (Podcast)

Non-Binding Guidance: FDA's Draft Guidance On Communication Of Scientific Information On Unapproved Uses Of Medical Products (Podcast)